Author:
Chaudhari Sonal R.,Lai Tiffany S.,Zakhour Mae,Myung Shin Sim,Baltayan Armine,Tan Hongying,Cohen Joshua G.
Subject
Obstetrics and Gynecology,Oncology
Reference32 articles.
1. AAFCPAs. LILETTA IUD May Offer Cost Savings to 340B Covered Entities. AAFCPAs. Published September 12, 2016. https://www.aafcpa.com/2016/09/12/liletta-iud-may-offer-cost-savings-to-340b-covered-entities/.
2. Prognostic significance of estrogen and progesterone receptor expression in LNG-IUS (Mirena) treatment of endometrial hyperplasia: An immunohistochemical study;Akesson;Acta Obstetricia et Gynecologica Scandinavica,2010
3. FDA Approves Medicines360’s LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years. Medicines360. Published November 14, 2022. https://medicines360.org/2022/11/14/fda-approves-medicines360s-liletta-levonorgestrel-releasing-intrauterine-system-52-mg-to-prevent-pregnancy-for-up-to-eight-years/.
4. Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia;Behnamfar;J Res Med Sci.,2014
5. SGO Clinical Practice Endometrial Cancer Working Group; Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Villella J, Herzog T, Abu Shahin F; Society of Gynecologic Oncology Clinical Practice Committee. Endometrial cancer: A review and current management strategies: Part I. Gynecol Oncol. 2014 Aug;134(2):385-92. doi: 10.1016/j.ygyno.2014.05.018. Epub 2014 Jun 4. Erratum in: Gynecol Oncol. 2014 Dec;135(3):625. Villella, Jeanine [corrected to Villella, Jeannine]. PMID: 24905773.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献